Mirna Therapeutics


Mirna Therapeutics is an Austin-based clinical-stage biopharmaceutical company dedicated to developing a broad pipeline of microRNA-based oncology therapeutics. Mirna recently completed its initial public offering and began trading Oct. 1 on the NASDAQ exchange as MIRN. Mirna was approved for a three year, $16.8M product development grant from the Cancer Prevention and Research Institute of Texas (CPRIT), an organization which funds groundbreaking cancer research and prevention programs and services in Texas. As the company initiated the grant, they faced accounting system challenges and timely reporting compliance.

Services Provided

  • CFO Services
  • NetSuite Implementation
  • Financial Operations Support Services

Consulting CFO Steers Successful Product Development

Mirna engaged Bridgepoint Consulting to provide accounting, financial, and IT consulting services to help aggregate the information needed to complete the CPRIT grant implementation and adhere to ongoing grant reporting requirements. Bridgepoint also provided accounting support services as Mirna underwent its IPO process. Jon Irvin, a seasoned Bridgepoint CFO was brought aboard as a consulting CFO in November of 2012 and joined Mirna as an employee in May of 2013.

Bridgepoint was engaged to help Mirna implement NetSuite to manage their accounting services and meet Sarbanes–Oxley compliance requirements. More recently Bridgepoint assisted Mirna with an equity reporting system migration and provided support for its initial 10-Q reporting.

What the Client Says

“Bridgepoint Consulting has been a great strategic partner and instrumental in many areas of our business—from helping us improve accounting processes for the CPRIT grant to enabling us to undergo a successful IPO. We’ve built a great relationship with Bridgepoint and continue to leverage their expertise.”

Alan Fuhrman CFO of Mirna